ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer
ASO Author Reflections
- 62 Downloads
The study commented upon was supported by an unrestricted grant provided by Roche. The authors have no conflicts of interest to disclose.
- 5.Duska LR, Java JJ, Cohn DE, Burger RA. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecol Oncol. 2015;139:221–7.CrossRefGoogle Scholar
© Society of Surgical Oncology 2018